Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 1.19
ZMH's Cash to Debt is ranked higher than
64% of the 475 Companies
in the Global Medical Devices industry.

( Industry Median: 2.15 vs. ZMH: 1.19 )
ZMH' s 10-Year Cash to Debt Range
Min: 0.05   Max: No Debt
Current: 1.19

Equity to Asset 0.68
ZMH's Equity to Asset is ranked higher than
74% of the 445 Companies
in the Global Medical Devices industry.

( Industry Median: 0.65 vs. ZMH: 0.68 )
ZMH' s 10-Year Equity to Asset Range
Min: 0.03   Max: 0.84
Current: 0.68

0.03
0.84
Interest Coverage 0.88
ZMH's Interest Coverage is ranked lower than
61% of the 259 Companies
in the Global Medical Devices industry.

( Industry Median: 231.38 vs. ZMH: 0.88 )
ZMH' s 10-Year Interest Coverage Range
Min: 0.88   Max: 9999.99
Current: 0.88

0.88
9999.99
F-Score: 4
Z-Score: 6.06
M-Score: -2.89
WACC vs ROIC
10.10%
10.94%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 20.97
ZMH's Operating margin (%) is ranked higher than
94% of the 459 Companies
in the Global Medical Devices industry.

( Industry Median: 6.13 vs. ZMH: 20.97 )
ZMH' s 10-Year Operating margin (%) Range
Min: 9.72   Max: 33.34
Current: 20.97

9.72
33.34
Net-margin (%) 14.20
ZMH's Net-margin (%) is ranked higher than
91% of the 459 Companies
in the Global Medical Devices industry.

( Industry Median: 4.35 vs. ZMH: 14.20 )
ZMH' s 10-Year Net-margin (%) Range
Min: 2.35   Max: 23.87
Current: 14.2

2.35
23.87
ROE (%) 9.68
ZMH's ROE (%) is ranked higher than
81% of the 446 Companies
in the Global Medical Devices industry.

( Industry Median: 5.76 vs. ZMH: 9.68 )
ZMH' s 10-Year ROE (%) Range
Min: 1.81   Max: 115.87
Current: 9.68

1.81
115.87
ROA (%) 6.51
ZMH's ROA (%) is ranked higher than
84% of the 477 Companies
in the Global Medical Devices industry.

( Industry Median: 2.94 vs. ZMH: 6.51 )
ZMH' s 10-Year ROA (%) Range
Min: 0.78   Max: 32.15
Current: 6.51

0.78
32.15
ROC (Joel Greenblatt) (%) 32.03
ZMH's ROC (Joel Greenblatt) (%) is ranked higher than
87% of the 476 Companies
in the Global Medical Devices industry.

( Industry Median: 9.33 vs. ZMH: 32.03 )
ZMH' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 14.87   Max: 119.58
Current: 32.03

14.87
119.58
Revenue Growth (3Y)(%) -7.00
ZMH's Revenue Growth (3Y)(%) is ranked higher than
59% of the 346 Companies
in the Global Medical Devices industry.

( Industry Median: 4.70 vs. ZMH: -7.00 )
ZMH' s 10-Year Revenue Growth (3Y)(%) Range
Min: -7   Max: 25.6
Current: -7

-7
25.6
EBITDA Growth (3Y)(%) -13.30
ZMH's EBITDA Growth (3Y)(%) is ranked higher than
63% of the 298 Companies
in the Global Medical Devices industry.

( Industry Median: 2.80 vs. ZMH: -13.30 )
ZMH' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -13.3   Max: 39.6
Current: -13.3

-13.3
39.6
EPS Growth (3Y)(%) -51.80
ZMH's EPS Growth (3Y)(%) is ranked higher than
52% of the 309 Companies
in the Global Medical Devices industry.

( Industry Median: 2.30 vs. ZMH: -51.80 )
ZMH' s 10-Year EPS Growth (3Y)(%) Range
Min: -51.8   Max: 41.7
Current: -51.8

-51.8
41.7
» ZMH's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

ZMH Guru Trades in Q1 2014

Jim Simons 355,760 sh (New)
Joel Greenblatt 45,597 sh (+1594.43%)
David Dreman 1,531 sh (+350.29%)
RS Investment Management 63,100 sh (+27.73%)
Pioneer Investments 348,679 sh (+11.44%)
HOTCHKIS & WILEY 1,599,304 sh (+5.13%)
John Rogers 952,482 sh (+2.55%)
Jean-Marie Eveillard 1,632 sh (unchged)
Vanguard Health Care Fund 2,146,200 sh (unchged)
Ray Dalio Sold Out
PRIMECAP Management 457,200 sh (-0.02%)
Bill Frels 661,009 sh (-0.31%)
Private Capital 156,250 sh (-1.19%)
Scott Black 126,647 sh (-1.69%)
Mario Gabelli 308,402 sh (-2.25%)
Jeff Auxier 95,527 sh (-2.33%)
Ken Fisher 171,570 sh (-3.96%)
Robert Olstein 67,000 sh (-5.63%)
Jeremy Grantham 1,732,793 sh (-24.26%)
Steven Cohen 212,136 sh (-32.55%)
Paul Tudor Jones 13,878 sh (-92.45%)
» More
Q2 2014

ZMH Guru Trades in Q2 2014

Andreas Halvorsen 603,193 sh (New)
Jim Simons 760,200 sh (+113.68%)
Robert Olstein 87,000 sh (+29.85%)
David Dreman 1,666 sh (+8.82%)
RS Investment Management 63,250 sh (+0.24%)
Steven Cohen 378,709 sh (unchged)
Scott Black Sold Out
Mario Gabelli 308,121 sh (-0.09%)
Ken Fisher 170,061 sh (-0.88%)
PRIMECAP Management 450,100 sh (-1.55%)
Jeff Auxier 93,417 sh (-2.21%)
Private Capital 151,365 sh (-3.13%)
Bill Frels 637,320 sh (-3.58%)
HOTCHKIS & WILEY 1,536,345 sh (-3.94%)
Paul Tudor Jones 12,470 sh (-10.15%)
Pioneer Investments 295,991 sh (-15.11%)
Vanguard Health Care Fund 1,779,800 sh (-17.07%)
John Rogers 753,063 sh (-20.94%)
Jean-Marie Eveillard 1,122 sh (-31.25%)
Jeremy Grantham 1,054,694 sh (-39.13%)
Joel Greenblatt 4,631 sh (-89.84%)
» More
Q3 2014

ZMH Guru Trades in Q3 2014

Louis Moore Bacon 155,000 sh (New)
Scott Black 86,763 sh (New)
Paul Tudor Jones 412,347 sh (+3206.71%)
John Rogers 1,047,358 sh (+39.08%)
Robert Olstein 108,000 sh (+24.14%)
Jeremy Grantham 1,117,893 sh (+5.99%)
David Dreman 1,721 sh (+3.30%)
RS Investment Management 64,515 sh (+2.00%)
Mario Gabelli 313,486 sh (+1.74%)
Ken Fisher 170,119 sh (+0.03%)
Pioneer Investments 289,618 sh (unchged)
Andreas Halvorsen Sold Out
Jeff Auxier 93,267 sh (-0.16%)
PRIMECAP Management 449,204 sh (-0.20%)
Bill Frels 630,696 sh (-1.04%)
HOTCHKIS & WILEY 1,470,345 sh (-4.30%)
Joel Greenblatt 4,418 sh (-4.60%)
Private Capital 135,920 sh (-10.20%)
Vanguard Health Care Fund 1,589,200 sh (-10.71%)
Jean-Marie Eveillard 873 sh (-22.19%)
Steven Cohen 261,800 sh (-30.87%)
Jim Simons 387,600 sh (-49.01%)
» More
Q4 2014

ZMH Guru Trades in Q4 2014

Ray Dalio 2,028 sh (New)
Jean-Marie Eveillard 873 sh (unchged)
Vanguard Health Care Fund 1,589,200 sh (unchged)
Louis Moore Bacon Sold Out
Pioneer Investments 289,174 sh (-0.15%)
Jeff Auxier 92,942 sh (-0.35%)
PRIMECAP Management 446,704 sh (-0.56%)
John Rogers 1,040,965 sh (-0.61%)
HOTCHKIS & WILEY 1,457,788 sh (-0.85%)
Private Capital 133,375 sh (-1.87%)
RS Investment Management 63,110 sh (-2.18%)
Mario Gabelli 304,667 sh (-2.81%)
Ken Fisher 164,121 sh (-3.53%)
Scott Black 81,302 sh (-6.29%)
Bill Frels 558,549 sh (-11.44%)
Steven Cohen 228,900 sh (-12.57%)
Jeremy Grantham 966,816 sh (-13.51%)
David Dreman 1,487 sh (-13.60%)
Joel Greenblatt 3,685 sh (-16.59%)
Robert Olstein 82,000 sh (-24.07%)
Jim Simons 182,200 sh (-52.99%)
Paul Tudor Jones 5,342 sh (-98.70%)
» More
» Details

Insider Trades

Latest Guru Trades with ZMH

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 40.50
ZMH's P/E(ttm) is ranked higher than
80% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 201.60 vs. ZMH: 40.50 )
ZMH' s 10-Year P/E(ttm) Range
Min: 9.08   Max: 61.06
Current: 40.5

9.08
61.06
Forward P/E 15.53
ZMH's Forward P/E is ranked higher than
94% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. ZMH: 15.53 )
N/A
PE(NRI) 40.50
ZMH's PE(NRI) is ranked higher than
81% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 140.40 vs. ZMH: 40.50 )
ZMH' s 10-Year PE(NRI) Range
Min: 9.07   Max: 61.01
Current: 40.5

9.07
61.01
P/B 3.05
ZMH's P/B is ranked higher than
75% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 4.25 vs. ZMH: 3.05 )
ZMH' s 10-Year P/B Range
Min: 1.31   Max: 6.22
Current: 3.05

1.31
6.22
P/S 5.74
ZMH's P/S is ranked higher than
59% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 3.68 vs. ZMH: 5.74 )
ZMH' s 10-Year P/S Range
Min: 1.82   Max: 8.19
Current: 5.74

1.82
8.19
PFCF 18.25
ZMH's PFCF is ranked higher than
93% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. ZMH: 18.25 )
ZMH' s 10-Year PFCF Range
Min: 9.54   Max: 44.68
Current: 18.25

9.54
44.68
POCF 14.35
ZMH's POCF is ranked higher than
91% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 78.33 vs. ZMH: 14.35 )
ZMH' s 10-Year POCF Range
Min: 6.88   Max: 31.71
Current: 14.35

6.88
31.71
EV-to-EBIT 26.75
ZMH's EV-to-EBIT is ranked higher than
82% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 73.27 vs. ZMH: 26.75 )
ZMH' s 10-Year EV-to-EBIT Range
Min: 6.8   Max: 43.4
Current: 26.75

6.8
43.4
Shiller P/E 29.51
ZMH's Shiller P/E is ranked higher than
92% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. ZMH: 29.51 )
ZMH' s 10-Year Shiller P/E Range
Min: 10.71   Max: 39.22
Current: 29.51

10.71
39.22
Current Ratio 4.13
ZMH's Current Ratio is ranked higher than
82% of the 469 Companies
in the Global Medical Devices industry.

( Industry Median: 2.51 vs. ZMH: 4.13 )
ZMH' s 10-Year Current Ratio Range
Min: 1.14   Max: 5.09
Current: 4.13

1.14
5.09
Quick Ratio 3.01
ZMH's Quick Ratio is ranked higher than
80% of the 469 Companies
in the Global Medical Devices industry.

( Industry Median: 1.89 vs. ZMH: 3.01 )
ZMH' s 10-Year Quick Ratio Range
Min: 0.71   Max: 3.69
Current: 3.01

0.71
3.69
Days Inventory 357.08
ZMH's Days Inventory is ranked higher than
56% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 166.67 vs. ZMH: 357.08 )
ZMH' s 10-Year Days Inventory Range
Min: 197.28   Max: 339.23
Current: 357.08

197.28
339.23
Days Sales Outstanding 94.80
ZMH's Days Sales Outstanding is ranked higher than
66% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 79.87 vs. ZMH: 94.80 )
ZMH' s 10-Year Days Sales Outstanding Range
Min: 56.27   Max: 93.39
Current: 94.8

56.27
93.39

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.75
ZMH's Dividend Yield is ranked lower than
72% of the 189 Companies
in the Global Medical Devices industry.

( Industry Median: 1.42 vs. ZMH: 0.75 )
ZMH' s 10-Year Dividend Yield Range
Min: 0.28   Max: 1.1
Current: 0.75

0.28
1.1
Dividend Payout 0.21
ZMH's Dividend Payout is ranked higher than
94% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. ZMH: 0.21 )
ZMH' s 10-Year Dividend Payout Range
Min: 0.15   Max: 0.24
Current: 0.21

0.15
0.24
Yield on cost (5-Year) 0.80
ZMH's Yield on cost (5-Year) is ranked lower than
71% of the 191 Companies
in the Global Medical Devices industry.

( Industry Median: 1.48 vs. ZMH: 0.80 )
ZMH' s 10-Year Yield on cost (5-Year) Range
Min: 0.28   Max: 1.1
Current: 0.8

0.28
1.1
Share Buyback Rate 100.00
ZMH's Share Buyback Rate is ranked higher than
99% of the 330 Companies
in the Global Medical Devices industry.

( Industry Median: -1.40 vs. ZMH: 100.00 )
ZMH' s 10-Year Share Buyback Rate Range
Min: 100   Max: -8.4
Current: 100

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 16.93
ZMH's Price/Net Current Asset Value is ranked higher than
76% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 327.00 vs. ZMH: 16.93 )
ZMH' s 10-Year Price/Net Current Asset Value Range
Min: 12.23   Max: 486.31
Current: 16.93

12.23
486.31
Price/Tangible Book 5.85
ZMH's Price/Tangible Book is ranked higher than
71% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 7.90 vs. ZMH: 5.85 )
ZMH' s 10-Year Price/Tangible Book Range
Min: 4.44   Max: 185.26
Current: 5.85

4.44
185.26
Price/DCF (Projected) 1.48
ZMH's Price/DCF (Projected) is ranked higher than
94% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. ZMH: 1.48 )
ZMH' s 10-Year Price/DCF (Projected) Range
Min: 0.58   Max: 2.31
Current: 1.48

0.58
2.31
Price/Median PS Value 1.65
ZMH's Price/Median PS Value is ranked higher than
64% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 1.40 vs. ZMH: 1.65 )
ZMH' s 10-Year Price/Median PS Value Range
Min: 0.58   Max: 2.68
Current: 1.65

0.58
2.68
Price/Peter Lynch Fair Value 4.10
ZMH's Price/Peter Lynch Fair Value is ranked higher than
93% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. ZMH: 4.10 )
ZMH' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.66   Max: 5.14
Current: 4.1

0.66
5.14
Price/Graham Number 3.22
ZMH's Price/Graham Number is ranked higher than
83% of the 524 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. ZMH: 3.22 )
ZMH' s 10-Year Price/Graham Number Range
Min: 1.36   Max: 22.07
Current: 3.22

1.36
22.07
Earnings Yield (Greenblatt) 3.70
ZMH's Earnings Yield (Greenblatt) is ranked higher than
79% of the 468 Companies
in the Global Medical Devices industry.

( Industry Median: 2.20 vs. ZMH: 3.70 )
ZMH' s 10-Year Earnings Yield (Greenblatt) Range
Min: 2.3   Max: 14.7
Current: 3.7

2.3
14.7
Forward Rate of Return (Yacktman) 4.94
ZMH's Forward Rate of Return (Yacktman) is ranked higher than
78% of the 218 Companies
in the Global Medical Devices industry.

( Industry Median: 4.94 vs. ZMH: 4.94 )
ZMH' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 4.8   Max: 45.7
Current: 4.94

4.8
45.7

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, STJ, EW » details
Traded in other countries:ZMH.Switzerland, ZIM.Germany, 0QQD.UK,
Zimmer Holdings Inc was incorporated in 2001. The Company designs, develops, manufactures and markets orthopaedic reconstructive, spinal and trauma devices, biologics, dental implants and related surgical products. It also provides other healthcare related services. Its products include orthopaedic reconstructive implants, spinal and trauma devices, biologics, dental implants and related surgical products. Its orthopaedic reconstructive devices restore function lost due to disease or trauma in joints such as knees, hips, shoulders and elbows. Its dental reconstructive implants restore function and aesthetics in patients who have lost teeth due to trauma or disease. Its spinal devices are utilized by orthopaedic surgeons and neurosurgeons in the treatment of degenerative diseases, deformities and trauma in all regions of the spine. Its trauma products are devices used to reattach or stabilize damaged bone and tissue to support the body's natural healing process. The Company has its operations in more than 25 countries and markets its products in more than 100 countries. The Company operates in a single industry but have three reportable geographic segments, the Americas, Europe and Asia Pacific. The Americas, which is comprised of the U.S. and includes other North, Central and South American markets; Europe, which is comprised of Europe and includes the Middle East and African markets; and Asia Pacific, which is comprised of Japan and includes other Asian and Pacific markets. The Company's customers include orthopaedic surgeons, neurosurgeons, oral surgeons, dentists, hospitals, stocking distributors, healthcare dealers and, in their capacity as agents, healthcare purchasing organizations or buying groups. It markets and sells its products through three channels; direct to healthcare institutions, such as hospitals, referred to as direct channel accounts; through stocking distributors and healthcare dealers; and directly to dental practices and dental laboratories. The Company operates distribution facilities domestically in Warsaw, Indiana; Southaven, Mississippi; and Carlsbad, California and internationally in Australia, Austria, Belgium, Canada, the Czech Republic, China, Finland, France, Germany, Hong Kong, India, Italy, Japan, Korea, Malaysia, the Netherlands, New Zealand, Portugal, Russia, Singapore, South Africa, Spain, Sweden, Switzerland, Taiwan, Thailand and the United Kingdom. The Company competes with the DePuy Synthes Companies of Johnson & Johnson, Stryker Corporation, Biomet, Inc., and Smith & Nephew plc. It protects its proprietary rights through a variety of methods, including confidentiality agreements and proprietary information agreements with vendors, employees, consultants and others who may have access to proprietary information. The Company is subject to government regulation in the countries in which it conducts business.
» More Articles for ZMH

Headlines

Articles On GuruFocus.com
I think Zimmer Will Outperform S&P 500 Performance Dec 04 2014 
Weekly 52-Week Highs Highlight: TGT, THI, TRI, ZMH Nov 17 2014 
Medical Technology Company Offers Investment Opportunity Sep 25 2014 
Simon Properties Reports Insider Trades Mar 13 2013 
Stryker Corporation (SYK) Dividend Stock Analysis Jan 11 2013 
These 5 Stocks Are Most Hated by Big Investors Nov 07 2012 
52-Week High Companies: ZMH, CVX, V, REGN, DFS Sep 10 2012 
5 Healthcare Stocks You Should Know About Mar 31 2012 
5 Healthcare Stocks to Consider for 2012 Mar 27 2012 
Edward Owens’ Vanguard Health Care Fund Biggest Buys in Fourth Quarter Jan 30 2012 


More From Other Websites
ZIMMER HOLDINGS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Mar 30 2015
Mar 30, 2015 Zimmer Announces Clearance by the European Commission of the Pending Biomet Merger Mar 30 2015
Zimmer Announces Clearance by the European Commission of the Pending Biomet Merger Mar 30 2015
[$$] EU Approves Biomet-Zimmer Merger Mar 30 2015
Zimmer wins EU approval for $13.4 bln Biomet acquisition Mar 30 2015
Mar 27, 2015 Zimmer Celebrates Key Milestones For NexGen Complete Knee System Mar 27 2015
Mar 27, 2015 Zimmer Debuts New Modular External Fixation System Mar 27 2015
Zimmer Debuts New Modular External Fixation System Mar 27 2015
Zimmer Celebrates Key Milestones For NexGen Complete Knee System Mar 27 2015
Mar 26, 2015 Zimmer Launches New Patient Education And Engagement Mobile App For Gel-One Hyaluronate Mar 26 2015
Mar 26, 2015 Zimmer Announces New Testing Milestone For Vitamin E Advanced Bearing Technology Mar 26 2015
Zimmer Announces New Testing Milestone For Vitamin E Advanced Bearing Technology Mar 26 2015
Zimmer Launches New Patient Education And Engagement Mobile App For Gel-One Hyaluronate Mar 26 2015
Mar 25, 2015 New Approach To Total Knee Replacement - Zimmer Creates TKA Outpatient Program Mar 25 2015
New Approach To Total Knee Replacement - Zimmer Creates TKA Outpatient Program Mar 25 2015
Mar 25, 2015 Zimmer Announces Clearance by the Japan Fair Trade Commission of the Pending Biomet... Mar 25 2015
ZIMMER HOLDINGS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Mar 25 2015
Zimmer Announces Clearance by the Japan Fair Trade Commission of the Pending Biomet Merger Mar 25 2015
ZIMMER HOLDINGS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a... Mar 19 2015
EU to clear Zimmer's $13.4 billion Biomet deal - sources Mar 18 2015
EU to clear Zimmer's $13.4 bln Biomet deal -sources Mar 18 2015
EU regulators to clear Zimmer's $13.4 bln buy of Biomet - sources Mar 18 2015
ZIMMER HOLDINGS INC Files SEC form 8-K, Other Events Mar 18 2015
PRESS DIGEST- New York Times business news - March 18 Mar 17 2015
Mar 16, 2015 Zimmer Announces First Clinical Use of Vivacit-E Liner for Trabecular Metal Reverse... Mar 16 2015
Zimmer Announces First Clinical Use of Vivacit-E Liner for Trabecular Metal Reverse Shoulder System Mar 16 2015
ZIMMER HOLDINGS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events,... Mar 12 2015
ZIMMER HOLDINGS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Mar 11 2015
Zimmer Offers $7.65 Billion of Debt Mar 11 2015
Mar 11, 2015 Zimmer Holdings, Inc. Agrees to Sell $7.65 Billion of Senior Notes in Connection with... Mar 11 2015
Zimmer Holdings, Inc. Agrees to Sell $7.65 Billion of Senior Notes in Connection with Pending Merger... Mar 11 2015
ZIMMER HOLDINGS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Mar 10 2015
Feb 24, 2015 Zimmer Holdings, Inc. Announces Quarterly Dividend for First Quarter of 2015 Feb 24 2015
Feb 10, 2015 Zimmer Provides Update on the European Commission Review Process Relating to the... Feb 12 2015
Zimmer beats 4Q profit forecasts Jan 29 2015
BUZZ-U.S. STOCKS ON THE MOVE- Automobile stocks, Kite Pharma, Zimmer Jan 05 2015
Dec 30, 2014 Zimmer Holdings to Present at 33rd Annual J.P. Morgan Healthcare Conference Dec 30 2014
Dec 15, 2014 Zimmer Holdings, Inc. Announces Quarterly Dividend for Fourth Quarter of 2014 Dec 15 2014
Dec 12, 2014 Zimmer Holdings Names Michael Farrell to Board of Directors Dec 12 2014
Dec 4, 2014 Zimmer Provides Update on the European Commission Review Process Relating to the Pending... Dec 04 2014
Nov 18, 2014 Zimmer Provides Update on the European Commission Review Process Relating to the... Nov 18 2014
Nov 17, 2014 Zimmer's Virage® OCT Spinal Fixation System Wins Life Science Alley Award Nov 17 2014
Nov 12, 2014 Zimmer Spine Showcases its Expanding Business and a Dozen New Products at the 2014 NASS... Nov 12 2014
Nov 10, 2014 Zimmer Announces FDA Clearance of the Stand-alone Optio-C® Anterior Cervical System... Nov 10 2014
Zimmer will become Zimmer Biomet after acquisition Oct 30 2014
Oct 30, 2014 Zimmer Announces Executive Leadership Team and New Name of Combined Company Following... Oct 30 2014
BUZZ-Zimmer Holdings Inc: Posts better-than-expected profit Oct 23 2014
Zimmer beats Street 3Q forecasts Oct 23 2014
EU regulators extend Zimmer, Biomet deal deadline to March 11 Oct 10 2014
EU regulators open extensive probe into Zimmer, Biomet deal Oct 03 2014
EU to extend Zimmer, Biomet probe, clear Eli Lilly, Novartis deal - sources Oct 02 2014
EU decision on Zimmer's $13.4 billion Biomet deal expected by October 3 Sep 01 2014
Zimmer 2Q profit climbs 16 percent Jul 24 2014
EU regulators halt review of Zimmer's $13 billion Biomet bid Jun 12 2014
EU to decide on Zimmer's $13.4 billion Biomet deal by July 9 Jun 04 2014
S&N says 'no interest' in deals in reconstructive surgery May 01 2014
Zimmer to buy Biomet for $13.35 bn Apr 24 2014
Zimmer to buy Biomet for $13.35 billion in latest consolidation Apr 24 2014
Zimmer buying Biomet in deal valued at $13.35B Apr 24 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK